Bristol Myers Squibb Reports Interim Phase 1 Data for CAR T-Cell Therapy in Multiple Sclerosis

Bristol Myers Squibb reported interim Phase 1 data from the Breakfree-2 study for its CAR T-cell therapy, zolacabtagene autoleucel (zola-cel), indicating that all 60 patients at the second dose level remained off disease-modifying therapies. Among evaluable patients with progressive multiple sclerosis, 92% showed stable or improved disability, with no new MRI activity reported. Safety concerns included cytokine release syndrome in 42.4% of patients and neurotoxicity in 7.6%, along with a noted fatal case of septic pneumonia.